BPC-157 and TB-500 operate through distinct but overlapping repair mechanisms. The question of synergy — whether the combination exceeds the sum of parts — is being answered in preclinical models.
Peptide research in preclinical injury models has increasingly moved beyond single-compound investigations toward multi-agent combination protocols. Two compounds that have drawn particular attention for co-administration studies are Body Protection Compound-157 (BPC-157) — a synthetic pentadecapeptide derived from gastric juice protein — and TB-500, a synthetic analog of the endogenous protein Thymosin Beta-4 (Tβ4). Both have accumulated substantial preclinical literature as individual agents. The more recent and scientifically compelling question is whether their co-administration in defined injury models yields outcomes that neither compound alone can fully replicate.
This article synthesizes available preclinical evidence on the mechanisms underlying each peptide, maps their overlapping and complementary pathways, reviews available co-administration data, and discusses the mechanistic rationale for BPC-157 TB-500 synergy as a research hypothesis. All data cited refers exclusively to preclinical, in vitro, or animal-model research. No conclusions regarding human efficacy or safety are implied or should be inferred.
For researchers sourcing compounds for preclinical investigations, our BPC-157 capsules (Batch BH-250112, 99.71% purity, independently verified) and TB-500 capsules (Batch BH-250410, 99.53% purity) are supplied with full Certificates of Analysis for research qualification.
BPC-157 (sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) is a synthetic 15-amino-acid peptide with no known endogenous analogue. Its preclinical activity profile is remarkably broad, with documented effects across gastrointestinal, musculoskeletal, vascular, and neurological tissue models in rodent studies.
Nitric Oxide (NO) Pathway Modulation: BPC-157 interacts with the nitric oxide system in a context-sensitive manner. Sikiric et al. (2016) demonstrated that BPC-157 counteracts both NOS inhibitor (L-NAME)-induced and NOS over-stimulation (L-arginine)-induced vascular pathology in rat models, suggesting a stabilizing rather than simply stimulatory or inhibitory role. This NO modulation is mechanistically relevant to vasodilation, blood flow regulation, and tissue oxygenation in injury sites.
VEGF Upregulation and Angiogenesis: A consistent finding across BPC-157 preclinical studies is upregulation of vascular endothelial growth factor (VEGF) in injured tissue. Chang et al. (2011) reported dose-dependent VEGF elevation in transected tendon models treated with BPC-157, accompanied by accelerated neovascularization and tensile strength recovery. This angiogenic drive is foundational to BPC-157’s proposed role in connective tissue repair.
Growth Hormone Receptor Interaction: BPC-157 appears to sensitize or upregulate growth hormone (GH) receptor expression in target tissues. Sikiric et al. have proposed that this GH receptor interaction mediates some of BPC-157’s anabolic tissue effects, particularly in muscle and bone models, though the precise molecular mechanism remains an active area of preclinical investigation.
Tendon-to-Bone Healing: Multiple rodent studies have documented BPC-157’s effects on fibroblast proliferation and collagen synthesis in tendon and ligament models. The oral BPC-157 tendon repair rat studies on this site provide additional context on administration-route considerations for these endpoints.
TB-500 is a synthetic analog corresponding to the central active region of Thymosin Beta-4 (Tβ4), an endogenous 43-amino-acid protein expressed ubiquitously across mammalian tissues and present at particularly high concentrations in platelets and wound fluids. The active fragment corresponds to the LKKTL-containing actin-binding domain.
Actin Sequestration and Polymerization: Thymosin Beta-4’s primary molecular function is G-actin (monomeric actin) sequestration. By binding G-actin, Tβ4 and its synthetic analogs regulate the ratio of free to polymerized actin, modulating cytoskeletal dynamics in migrating cells. This is critical for directional cell migration — a prerequisite for effective wound repair, tissue remodeling, and angiogenesis. Goldstein et al. (2012) reviewed this mechanism extensively, noting that the LKKTL motif is essential for actin-binding activity.
Cell Migration and Tissue Remodeling: In preclinical wound models, Tβ4 administration has been associated with accelerated keratinocyte and endothelial cell migration into wound beds, improved re-epithelialization, and enhanced collagen deposition. Kleinman et al. (2004) demonstrated that Tβ4 promotes corneal wound healing in mouse models through increased cell migration velocity, an effect attributable to actin cytoskeletal remodeling.
Anti-Inflammatory Signaling: TB-500 / Tβ4 modulates nuclear factor kappa-B (NF-κB) signaling, reducing pro-inflammatory cytokine production (IL-1β, TNF-α) in injury models. Smart et al. (2007) reported cardioprotective effects of Tβ4 in myocardial infarction models partly attributable to reduced inflammatory infiltration, alongside direct cardiomyocyte survival signaling via AKT/PKB pathways.
Nerve and Muscle Tissue Models: TB-500 preclinical literature includes evidence of activity in nerve regeneration models, with Tβ4 administration associated with Schwann cell migration enhancement and myelin-associated glycoprotein upregulation. In skeletal muscle injury models, Tβ4 has been linked to satellite cell activation — the muscle stem cell population responsible for myofiber repair.
The mechanistic rationale for studying BPC-157 TB-500 synergy in combination derives from the observation that their primary mechanisms are complementary rather than redundant. BPC-157’s dominant effects appear to be angiogenic (VEGF-driven neovascularization) and growth factor modulating (GH receptor, NO-system stabilization), whereas TB-500’s dominant effects are cytoskeletal (actin dynamics, cell migration) and anti-inflammatory (NF-κB, AKT signaling).
Effective tissue repair requires both adequate vascular supply to the injury site AND competent cellular migration/remodeling. A compound that drives angiogenesis without enhancing cell migration may be limited by the rate at which repair cells populate the newly vascularized space. Conversely, a compound that enhances cell migration without adequate vascular support may be limited by hypoxia and nutrient deprivation. This mechanistic gap creates the theoretical basis for testing whether co-administration in injury models produces outcomes not achievable with either compound alone.
For a broader review of how these peptides compare individually, see our BPC-157 vs TB-500 stack guide and the comprehensive 2026 systematic reviews on musculoskeletal applications.
| Pathway / Mechanism | BPC-157 | TB-500 | Overlap / Interaction |
|---|---|---|---|
| Nitric Oxide (NO) Modulation | Strong — bidirectional stabilization of NO system; counteracts NOS inhibition and over-stimulation | Indirect — anti-inflammatory effects reduce iNOS-driven NO overproduction in some models | Partial: both modulate vascular tone via different upstream nodes |
| VEGF / Angiogenesis | Strong — direct VEGF upregulation, neovascularization in tendon, bone, and GI models | Moderate — Tβ4 promotes endothelial cell migration; indirect angiogenic support | Additive potential: BPC-157 initiates vessel sprouting; TB-500 facilitates endothelial migration into sprouting vessels |
| Actin Polymerization / Cytoskeletal Dynamics | Minimal direct evidence | Primary mechanism — G-actin sequestration via LKKTL motif; regulates lamellipodia formation | Complementary: BPC-157 recruits cells via growth factor signaling; TB-500 enables directed migration once recruited |
| Anti-Inflammatory Signaling | Moderate — reduces oxidative stress markers; modulates eicosanoid pathways in GI models | Strong — NF-κB pathway inhibition; reduces IL-1β, TNF-α in wound and cardiac models | Additive potential: complementary targets within the inflammatory cascade |
| Growth Hormone / IGF Axis | Moderate — GH receptor upregulation proposed; IGF-1 pathway interactions in bone and muscle models | Limited direct evidence; AKT/PKB activation has downstream overlap with IGF-1 signaling | Possible convergence at AKT node |
| Nerve Regeneration | Moderate — BPC-157 promotes nerve regrowth in crushed nerve models; VEGF-mediated neural vascularization | Moderate — Tβ4 enhances Schwann cell migration; promotes myelination in peripheral nerve models | High overlap: both promote peripheral nerve repair via distinct but synergistic mechanisms (vascularization + cellular repair) |
| Fibroblast / Collagen Synthesis | Strong — fibroblast proliferation and collagen type I/III upregulation in tendon and wound models | Moderate — Tβ4 promotes fibroblast migration; moderate collagen synthesis effects | Additive: BPC-157 drives collagen production; TB-500 drives fibroblast positioning |
| Muscle Satellite Cell Activation | Limited direct evidence in satellite cell models | Moderate — Tβ4 associated with satellite cell activation and myoblast differentiation in muscle injury models | Potentially complementary: BPC-157 vascularizes injury site; TB-500 supports myogenic repair |
Direct head-to-head co-administration studies specifically combining BPC-157 and TB-500 remain relatively limited in the published preclinical literature as of 2025. The majority of combination evidence is extrapolated from parallel single-compound studies using similar models and endpoints, or from studies testing BPC-157 or TB-500 in combination with other agents. However, several observations from the injury model literature are relevant to the BPC-157 TB-500 synergy hypothesis.
A key methodological consideration in rodent injury model co-administration studies is the distinction between additive effects (combined outcome equals the sum of individual compound effects), synergistic effects (combined outcome exceeds the sum), and antagonistic effects (combined outcome is less than expected). Formal synergy assessments in preclinical peptide research typically employ Bliss independence or Loewe additivity models, though these frameworks are more commonly applied in pharmacological combination oncology research than in injury model peptide research.
| Injury Model | Compounds / Doses | Route | BPC-157 Alone Outcome | TB-500 Alone Outcome | Combination / Inferred Outcome | Reference Context |
|---|---|---|---|---|---|---|
| Achilles Tendon Transection (rat) | BPC-157: 10 µg/kg i.p.; TB-500 (Tβ4): 150 µg/wound | i.p. / local injection | Increased VEGF, accelerated fibroplasia, improved tensile strength at 4 weeks | Faster fibroblast migration into wound gap, improved collagen alignment | Mechanistically complementary endpoints suggest additive or synergistic potential; no direct combination data published | Sikiric et al. (tendon); Kleinman/Goldstein Tβ4 wound literature |
| Full-Thickness Skin Wound (mouse) | Tβ4: 100–300 ng/wound; BPC-157 oral gavage 10 µg/kg | Topical / oral | Accelerated granulation tissue formation; VEGF upregulation at wound margins | Enhanced keratinocyte migration; faster re-epithelialization; anti-inflammatory | Both compounds accelerate different phases of wound healing (vascular vs. epithelial); combination hypothesized to compress overall healing timeline | Goldstein et al. (2012); Sikiric preclinical wound models |
| Crush Nerve Injury (rat sciatic) | BPC-157: 10 µg/kg i.p. daily; Tβ4: 6 mg/kg i.p. | i.p. | Improved functional recovery scores; nerve fiber regeneration markers elevated; VEGF at injury site | Enhanced Schwann cell migration; improved myelination scores; AKT activation | Complementary mechanisms (vascularization + cellular repair); combination data not directly reported but mechanistic basis strong | Sikiric nerve crush studies; Philp et al. Tβ4 nerve literature |
| Skeletal Muscle Laceration (rat) | BPC-157: 10 µg/kg i.p.; Tβ4: 6 mg/kg i.p. | i.p. | Reduced fibrosis; improved muscle regeneration histology; GH receptor upregulation | Satellite cell activation; myoblast differentiation; reduced inflammatory infiltrate | BPC-157 provides vascular scaffold; TB-500 activates myogenic repair; combined protocol is mechanistically rational and under active preclinical investigation | Sikiric muscle models; Smart et al. cardiac/muscle Tβ4 studies |
| Medial Collateral Ligament Sprain (rat) | BPC-157: 2 µg/kg oral; Tβ4: topical 25 µg | Oral / topical | Ligament collagen organization improved; biomechanical testing showed tensile strength gains vs. control | Cell migration into ligament injury site enhanced; inflammation markers reduced at 72h | Additive outcomes expected based on non-overlapping primary mechanisms; direct combination trial data not yet published | BPC-157 ligament literature; Tβ4 connective tissue models |
| Gastric Mucosal Lesion (rat NSAID model) | BPC-157: 10 µg/kg i.p. or oral | i.p. / oral | Strong cytoprotective effect; lesion healing accelerated; NO-dependent mechanism | Limited data in GI models specifically | BPC-157 primary compound for GI mucosal models; TB-500 role in GI context less established | Sikiric GI model series |
| Tissue Type | BPC-157 Preclinical Evidence | TB-500 Preclinical Evidence | Overlap / Combination Interest |
|---|---|---|---|
| Tendon | Extensive — Achilles, patellar, rotator cuff models in rat; VEGF, collagen, fibroplasia endpoints | Moderate — Tβ4 in tendon fibroblast migration models; anti-inflammatory effects in tendinopathy | High — both compounds have tendon preclinical data; complementary mechanisms; most cited combination target in stacking discussions |
| Ligament | Moderate — MCL, ACL models; biomechanical and histological outcomes | Moderate — cell migration into ligament injury sites; reduced acute inflammation | High — similar mechanistic rationale to tendon models |
| Peripheral Nerve | Moderate-Strong — sciatic crush, anastomosis models; VEGF-mediated re-innervation | Moderate — Schwann cell migration; myelination; AKT signaling in nerve repair | High — nerve repair requires both vascular supply (BPC-157) and cellular competence (TB-500) |
| Skeletal Muscle | Moderate — laceration and crush models; reduced fibrosis; GH pathway | Strong — satellite cell activation; myoblast differentiation; cardiac muscle models | Moderate-High — TB-500 leads in myogenic pathway; BPC-157 supports vascularization |
| Gastrointestinal Mucosa | Extensive — BPC-157 derived from gastric juice protein; robust cytoprotective evidence in multiple GI lesion models | Limited — sparse GI-specific Tβ4 data | Low-Moderate — BPC-157 primary compound; limited evidence for TB-500 in GI context |
| Bone | Moderate — fracture healing models; periosteal cell proliferation; GH receptor involvement | Limited — some Tβ4 data in bone marrow cell contexts; anti-inflammatory effects relevant | Moderate — BPC-157 more established in bone models |
| Cardiac Muscle | Limited — some protective data in ischemia models, primarily through NO/vascular mechanisms | Strong — Smart et al. cardiac infarction model; AKT cardiomyocyte survival; cardiomyocyte migration | Moderate — TB-500 primary compound for cardiac models; BPC-157 as adjunct |
| Skin / Wound | Moderate — BPC-157 accelerates granulation tissue formation and re-epithelialization | Strong — extensive Tβ4 wound healing literature; keratinocyte migration; original application for topical use | High — both have wound healing data; TB-500 leads in skin models but BPC-157 provides complementary angiogenic support |
| Spinal Cord | Limited — some neuroprotective data in rat contusion models | Limited — emerging data on Tβ4 in CNS injury models | Low-Moderate — both emerging in CNS contexts; insufficient evidence for confident combination protocol design |
The preclinical case for BPC-157 TB-500 synergy rests on three mechanistic pillars: pathway complementarity, temporal phase alignment, and tissue-specificity overlap.
As detailed in Table 1, BPC-157 and TB-500 operate primarily through non-overlapping molecular nodes. BPC-157’s dominant effects — VEGF upregulation, NO system stabilization, GH receptor sensitization, and fibroblast proliferation — address the supply side of tissue repair: establishing vascular architecture, delivering growth factors, and driving the production of structural matrix components.
TB-500’s dominant effects — G-actin sequestration, lamellipodia formation in migrating cells, NF-κB anti-inflammatory signaling, AKT/PKB cell survival signaling, and satellite cell activation — address the cellular competence side of repair: ensuring that repair cells can migrate directionally, survive in the injury microenvironment, and execute their tissue-specific repair programs.
This division of labor suggests that the two compounds are addressing different rate-limiting steps in the repair process rather than competing for the same molecular targets. When both steps are rate-limiting — which is the case in most acute injury models — co-administration is mechanistically expected to outperform either agent alone.
Tissue repair proceeds through overlapping but temporally structured phases: hemostasis (minutes to hours), inflammation (hours to days), proliferation (days to weeks), and remodeling (weeks to months). The preclinical evidence for each compound maps somewhat differently onto these phases.
TB-500’s anti-inflammatory properties are most relevant in the early inflammatory phase (within hours to 72 hours post-injury), when NF-κB-driven cytokine production determines the extent of secondary tissue damage and the character of the healing response. BPC-157’s angiogenic and growth factor effects are most critical during the proliferative phase (days 3–21 in rodent models), when neovascularization of the repair zone is essential for delivering nutrients, oxygen, and circulating repair cells to the injury site.
Importantly, these phases are not cleanly sequential — they overlap significantly — which means simultaneous administration of both compounds is likely to address relevant mechanisms concurrently rather than requiring staged delivery protocols. This is an important practical consideration for preclinical protocol design: simultaneous administration at the time of injury onset or shortly thereafter may capture the relevant window for both compounds’ primary mechanisms.
Table 3 identifies tendon, ligament, peripheral nerve, and skin/wound as the tissue types with the strongest preclinical evidence for both compounds individually. These overlapping tissue targets represent the most defensible sites for combination protocol design, as both compounds have established preclinical activity in those tissues and their mechanisms remain complementary within those tissue microenvironments.
The tendon model is particularly instructive. Tendon repair is constrained by the tissue’s inherently poor vascular supply, slow cellular turnover, and limited intrinsic repair capacity. BPC-157 directly addresses the vascular limitation through VEGF upregulation. TB-500 addresses the cellular limitation through fibroblast and tenocyte migration enhancement. Co-administration in tendon models is therefore mechanistically well-grounded and represents the strongest available rationale for preclinical combination studies in this tissue.
For researchers interested in the individual compound evidence base, our BPC-157 benefits research overview and the beginner’s guide to research peptides provide accessible entry points into the broader literature. For bioavailability considerations relevant to oral administration of both compounds, see our oral vs injectable peptide bioavailability analysis.
The most significant limitation of the current BPC-157 TB-500 synergy literature is the scarcity of formal head-to-head co-administration studies with direct statistical comparison of combination vs. individual compound outcomes. The majority of the mechanistic case for synergy is constructed by inference from parallel single-compound studies, not from dedicated combination trials with appropriate controls.
This is not unusual in preclinical peptide research — combination studies are methodologically expensive, requiring four arms (vehicle control, compound A, compound B, A+B combination) with sufficient power to detect interaction effects above additive expectations. Such studies are rarely funded in the academic settings where most BPC-157 and TB-500 research originates.
Researchers designing preclinical protocols to formally test BPC-157 TB-500 synergy should consider the Bliss independence model or Loewe additivity framework as the statistical basis for defining synergy versus additivity, pre-register endpoint selection, and power studies to detect interaction effects rather than simply main effects.
Neither BPC-157 nor TB-500 has a well-characterized dose-response curve across multiple injury models. BPC-157 exhibits a known inverted U-shaped dose-response in some GI models (Sikiric et al.), with very high doses showing diminished or reversed effects. Whether similar non-monotonic dose responses occur in musculoskeletal models for either compound, and whether combination dosing shifts these curves, is unknown. Combination studies should therefore include multiple dose levels rather than fixed single doses.
The available preclinical literature for BPC-157 includes studies using intraperitoneal, intragastric (oral), subcutaneous, and local injection routes. TB-500 literature is primarily intraperitoneal or systemic injection-based, with some topical wound application data. Whether the bioavailability profiles of both compounds, particularly after oral administration in enteric formulations, are sufficient to produce the tissue-level concentrations demonstrated in injection-based studies is an important open question. Our bioavailability analysis addresses this in depth.
Virtually all preclinical data for both compounds comes from Sprague-Dawley or Wistar rat models, with some mouse wound healing data for TB-500/Tβ4. The degree to which these findings translate across species — including, hypothetically, to higher mammalian systems — remains entirely unknown. Significant species differences in peptide pharmacokinetics, receptor expression patterns, and repair biology make extrapolation beyond rodent models scientifically unjustified without additional preclinical evidence.
There are no published randomized controlled trials, observational studies, or case series involving BPC-157, TB-500, or their combination in human subjects. Any claims of human efficacy for these compounds are unsupported by peer-reviewed evidence. All compounds discussed in this article are supplied and described strictly as Research Use Only (RUO) materials for preclinical investigation.
The preclinical case for BPC-157 TB-500 synergy in injury models is mechanistically compelling. The two compounds operate through fundamentally different primary pathways — BPC-157 through angiogenic and growth factor modulation, TB-500 through cytoskeletal dynamics and anti-inflammatory signaling — that are complementary rather than redundant in the context of tissue repair. Tissues with the highest preclinical evidence overlap (tendon, ligament, peripheral nerve, skin/wound) represent the most defensible targets for formal combination protocol design.
However, the field is currently ahead of the formal combination data: the mechanistic rationale for co-administration is stronger than the direct head-to-head preclinical evidence base. Dedicated co-administration studies with appropriate statistical frameworks for synergy detection represent an important gap in the literature. Researchers with access to appropriate preclinical models are well-positioned to contribute to this area.
For preclinical researchers requiring high-purity, COA-verified materials, our shop provides both BPC-157 (Batch BH-250112, 99.71% purity by HPLC) and TB-500 (Batch BH-250410, 99.53% purity by HPLC) in oral enteric capsule format, with full documentation available at our COA page.
All research compounds referenced in this article are available from Biohacker.dev-up.click as Research Use Only (RUO) materials. Quality verification documentation includes:
These compounds are supplied exclusively to researchers for preclinical laboratory use. They are not approved for human administration and are not intended to diagnose, treat, cure, or prevent any disease.
TB-500 is a synthetic analog of Thymosin Beta-4 (Tβ4), an endogenous 43-amino-acid protein found in high concentrations in platelets and wound fluids across mammalian species. In preclinical research, TB-500 typically refers to a synthetic peptide fragment corresponding to the LKKTL actin-binding domain of Tβ4, which is responsible for the protein’s cell migration-promoting and anti-inflammatory activities. TB-500 is studied in preclinical injury models for its effects on cytoskeletal dynamics, wound healing, nerve regeneration, and inflammatory modulation. It is a Research Use Only compound with no approved therapeutic applications.
BPC-157 is a synthetic pentadecapeptide (15 amino acids) with no known endogenous source, whose preclinical activity centers on the nitric oxide system, VEGF-driven angiogenesis, growth hormone receptor sensitization, and fibroblast collagen synthesis. TB-500 is a synthetic Thymosin Beta-4 analog whose primary mechanism involves G-actin sequestration to regulate cytoskeletal dynamics in migrating repair cells, along with NF-κB anti-inflammatory signaling and AKT cell-survival pathway activation. BPC-157’s primary effects are largely extracellular and vascular (building the scaffold and blood supply for repair), whereas TB-500’s primary effects are intracellular and cell-migration focused (enabling repair cells to populate and remodel the injury site). This mechanistic divergence — rather than redundancy — is what makes their co-administration in injury models a subject of active preclinical interest.
In preclinical pharmacology, synergy refers to a combination effect that exceeds what would be expected if both compounds were simply adding their individual effects together — formally defined as exceeding the Bliss independence or Loewe additivity prediction for the combination. This is distinguished from simple additivity (the combination equals the sum of parts) and from antagonism (the combination is less effective than expected). For BPC-157 and TB-500, the preclinical synergy hypothesis proposes that their non-overlapping primary mechanisms address different rate-limiting steps in tissue repair, such that combining them removes multiple simultaneous bottlenecks — potentially producing outcomes neither could achieve alone even at higher individual doses. Establishing formal synergy requires controlled combination studies with appropriate statistical designs, which remain limited in the current published literature for this specific compound pair.
Well-designed preclinical combination peptide studies require at minimum four experimental groups: vehicle control, compound A alone, compound B alone, and the A+B combination. Adequate statistical power for detecting interaction effects — not just main effects — typically requires larger group sizes than single-compound studies. Endpoint selection should be pre-specified and mechanistically motivated: for BPC-157 and TB-500, relevant endpoints include VEGF expression and vascular density (BPC-157 primary endpoints), actin-organization markers and cell migration velocity (TB-500 primary endpoints), and composite functional outcomes such as tensile strength or histological repair scoring (combination endpoints). Dose-response data for each compound independently should ideally be established before combination testing to identify doses near the EC50 range, which maximizes sensitivity for detecting synergistic interactions. Route of administration should be consistent across all arms.
Biohacker.dev-up.click supplies both BPC-157 and TB-500 in enteric capsule format for research use. Enteric capsules are designed to resist dissolution in the acidic gastric environment and release their contents in the small intestine, which is particularly relevant for peptide stability and absorption in oral administration protocols. BPC-157 has a well-established oral bioavailability preclinical profile — multiple rodent studies have demonstrated comparable efficacy via oral gavage versus intraperitoneal injection at appropriate doses, particularly for GI mucosal and systemic endpoints. Oral bioavailability data for TB-500 in enteric formulations is more limited, and researchers designing oral administration protocols should account for this when selecting routes and doses. All products are supplied with independent third-party Certificates of Analysis verifying purity (BPC-157 Batch BH-250112: 99.71%; TB-500 Batch BH-250410: 99.53%) and are available from our shop for qualified preclinical research purposes.
For the full BPC-157 compound profile, see BPC-157 Benefits: What the Research Actually Shows. For the TB-500 compound overview, see the BPC-157 vs TB-500 research stack guide.
All Biohacker compounds are for laboratory and scientific research use only. They are not intended for human or veterinary use, clinical application, or diagnostic purposes.